Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or non-pregnant women, 18 years of age or older with a suspected complicated urinary tract infection with an onset of symptoms 72 hours or less prior to study entry
Patients must present with a least one sign or symptom of a lower UTI (dysuria, urgency, frequency, suprapubic pain) or for spinal cord injury patients if such symptoms are not present, at least one of the following: fever (T \> 38º C or 100.4º F orally), onset of urinary incontinence, increased spasticity, autonomic hyperreflexia, increased sweating, or cloudy and odorous urine.
Patients must have at least one of the underlying conditions
* Indwelling urinary catheter or intermittent catheterization
* 100 mL of residual urine after voiding
* Neurogenic bladder
* Obstruction due to nephrolithiasis, tumor or fibrosis
* Urinary retention due to benign prostatic hypertrophy, bladder cancer or other urological anatomic abnormalities
* Patients must have pyuria prior to enrollment (within 48 hours) defined as \> 10 leukocytes/mm3 in unspun urine by hemocytometer or \> 5 leukocytes/hpf in resuspended sediment of centrifuged urine
* Patients must have one clean-catch, midstream urine culture or culture from catheter (obtained using sterile technique, not from a Foley bag) that was obtained within 48 hours of enrollment and had a positive results:
1. Defined as \>= 100000 CFU/mL (\>= 10000 CFU/mL for S. saprophyticus) for a causative pathogen
2. If more than 1 pathogen is identified, each should be present at a colony count \>= 100000 CFU/mL (\>= 10000 CFU/mL for S. saprophyticus) to be included in the analysis
3. For catheterized patients two or more pathogens (\>= 100000 CFU/mL) (\>= 10000 CFU/mL for S. saprophyticus) isolated from a baseline urine culture will be considered contaminants unless simultaneous blood culture yields the same pathogen(s)
4. The causative pathogen must be susceptible to ciprofloxacin on in vitro susceptibility testing
5. Enrollment and start of treatment is permitted prior to the availability of the culture report
You may not be if
Have a history of allergy to quinolones
Are unable to take or inability to tolerate oral medications
History of prostatitis or epididymitis
Have signs and symptoms of pyelonephritis \[all of the following: fever (T\>38° C/100.4° F orally), chills, and flank pain or costovertebral angle tenderness\]
Have an intractable infection requiring \> 14 days of therapy
Have an uncomplicated UTI
Have a renal transplant
Have ileal loops or vesico-ureteral reflux
Have a ciprofloxacin-resistant pathogen upon urine or blood culture
Have received systemic antimicrobial therapy within 48 hours prior to enrollment
Have a neutrophil count \<1000/mm3, CD4 \< 200/mm3 or other conditions associated with significant depression in host defense; HIV testing is not mandatory
Have a requirement for concomitant systemic antibacterial therapy with agents not specified in this protocol
Have significant liver impairment (baseline SGOT or SGPT and/or total bilirubin greater than 3 times the upper limit of normal)
Have significant renal impairment (serum creatinine \> 3.0 mg/dl or creatinine clearance \< 30 mL/min/1.73 m2)
Have a history of tendinopathy associated with fluoroquinolones
Are pregnant, nursing or in whom pregnancy cannot be excluded or unreliable contraception is being used
Have been diagnosed with a rapidly fatal underlying disease (death expected within 6 months)
Have a requirement for concomitant administration of sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminum or calcium
Have been previously enrolled in this clinical study
Have been taking an investigational drug in the last 30 days
Have a history of a UTI or bacteruria with a urinary pathogen resistant to a fluoroquinolone within 6 months prior to current UTI episode
Any of the following signs of sepsis:
Systolic blood pressure \< 90mm or a decrease of \> 40mm from baseline
Hypothermia (T\< 35.6°C, core)
Unexplained metabolic acidosis (pH \< 7.3 with BE \>= 5mmol/L or elevated lactate level)
PaO2 \< 75 mm/Hg on room air or PaO2 /FIO2 ratio \< 250
Acute renal failure (urine output \< 0.5mL/kg/h for \>= 1h)
DIC ( PTT, PT, or platelets \< 1/2 baseline or \< 100,000)
Acute deterioration in mental state
Hemodynamic state (CI \> 4L/min/m2 + SVR \< 800 dyn-sec/cm-5)15
Clareo Health | Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
